Biomarkers in Modern Healthcare: Types, Detection Methods, and Their Role in Transforming Patient Care
DOI:
https://doi.org/10.58445/rars.2887Keywords:
Biomarkers in Healthcare, Modern Healthcare, BiomarkersAbstract
Biomarkers are measurable indicators of biological processes that play a critical role in early disease detection, prognosis, and informing treatment strategies. This literature review explores the various types of biomarkers, including molecular, physiological, radiographic, and histological, while emphasizing their clinical significance in diagnosing diseases such as cancer, cardiovascular disease, and neurodegenerative disorders. The review also compares widely used detection techniques, such as ELISA, chromatography, and mass spectrometry, with emphasis on their strengths and limitations. Emerging technologies like the digital ELISA and LC-MS are improving sensitivity and specificity, enhancing clinical utility at lower concentrations and greater accuracy. Despite the numerous advantages, such as non-invasive sampling and cost-effectiveness, challenges remain regarding consistent specificity across all biomarkers and translating surrogate endpoints into meaningful patient outcomes. Future innovations like AI-based analysis and genetic sequencing are expected to expand biomarker discovery and application. As research progresses, biomarkers are likely to become increasingly integrated into healthcare, offering powerful tools for improving diagnosis, treatment, and patient outcomes.
References
O. of the Commissioner, “FDA Facts: Biomarkers and Surrogate Endpoints,” FDA, Feb. 2019, Accessed: July 20, 2025. [Online]. Available: https://www.fda.gov/about-fda/innovation-fda/fda-facts-biomarkers-and-surrogate-endpoints
“Cancer biomarkers - Henry - 2012 - Molecular Oncology - Wiley Online Library.” Accessed: July 20, 2025. [Online]. Available: https://febs.onlinelibrary.wiley.com/doi/10.1016/j.molonc.2012.01.010
“HER2 as a Prognostic Factor in Breast Cancer | Oncology | Karger Publishers.” Accessed: July 20, 2025. [Online]. Available: https://karger.com/ocl/article-abstract/61/Suppl.%202/67/237347/HER2-as-a-Prognostic-Factor-in-Breast-Cancer?redirectedFrom=fulltext
R. M. Califf, “Biomarker definitions and their applications,” Exp. Biol. Med., vol. 243, no. 3, pp. 213–221, Feb. 2018, doi: 10.1177/1535370217750088.
“Exploring the history behind ELISA.” Accessed: July 20, 2025. [Online]. Available: https://www.news-medical.net/whitepaper/20231211/Exploring-the-history-behind-ELISA.aspx
“(PDF) Pre-analytical Sample Handling Standardization for Reliable Measurement of Metabolites and Lipids in LC-MS-based Clinical Research.” Accessed: July 20, 2025. [Online]. Available: https://www.researchgate.net/publication/368577294_Pre-analytical_Sample_Handling_Standardization_for_Reliable_Measurement_of_Metabolites_and_Lipids_in_LC-MS-based_Clinical_Research
“Molecular Biomarkers - Omar F. Laterza, Ronald C. Hendrickson, John A. Wagner, 2007.” Accessed: July 20, 2025. [Online]. Available: https://journals.sagepub.com/doi/abs/10.1177/009286150704100504
S. Ravindran et al., “The role of molecular biomarkers in the diagnosis, prognosis, and treatment stratification of oral squamous cell carcinoma: A comprehensive review,” J. Liq. Biopsy, vol. 7, p. 100285, Mar. 2025, doi: 10.1016/j.jlb.2025.100285.
“Assessment of Changes in Physiological Markers in Different Body Fluids at Rest and after Exercise.” Accessed: July 20, 2025. [Online]. Available: https://www.mdpi.com/2072-6643/14/21/4685
“Frontiers | Using physiological biomarkers in forensic psychiatry: a scoping review.” Accessed: July 20, 2025. [Online]. Available: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1580615/full
J. Mens, E. Masthoff, S. Bogaerts, and P. Heus, “Using physiological biomarkers in forensic psychiatry: a scoping review,” Front. Psychiatry, vol. 16, Apr. 2025, doi: 10.3389/fpsyt.2025.1580615.
“Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR) | Insights into Imaging | Full Text.” Accessed: July 20, 2025. [Online]. Available: https://insightsimaging.springeropen.com/articles/10.1186/s13244-019-0764-0
“Imaging biomarker roadmap for cancer studies | Nature Reviews Clinical Oncology.” Accessed: July 20, 2025. [Online]. Available: https://www.nature.com/articles/nrclinonc.2016.162
“Understanding Biomarkers and Why They’re So Important - Ezra.” Accessed: July 20, 2025. [Online]. Available: https://ezra.com/blog/biomarkers1
N. A. Giraldo, J. D. Peske, C. Sautès-Fridman, and W. H. Fridman, “Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology,” Virchows Arch. Int. J. Pathol., vol. 474, no. 4, pp. 463–474, Apr. 2019, doi: 10.1007/s00428-018-02517-1.
“Troponin: the biomarker of choice for the detection of cardiac injury - PMC.” Accessed: July 20, 2025. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC1277047/
“Iron and Alzheimer’s Disease: From Pathogenesis to Therapeutic Implications - PMC.” Accessed: July 20, 2025. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC6139360/
K. Tsai, S. Crespo, and S. Swaminathan, “The Role of Iron in Alzheimer’s Disease: A Promising Biomarker,” Apr. 07, 2024, Research Archive of Rising Scholars. doi: 10.58445/rars.1059.
“Earlier Diagnosis | Alzheimer’s Association.” Accessed: July 20, 2025. [Online]. Available: https://www.alz.org/alzheimers-dementia/research-and-progress/earlier-diagnosis
“Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of Mild Cognitive Impairment by the fully automated Lumipulse® platform | Fluids and Barriers of the CNS | Full Text.” Accessed: July 20, 2025. [Online]. Available: https://fluidsbarrierscns.biomedcentral.com/articles/10.1186/s12987-025-00620-5
“Distinguishing prognostic and predictive biomarkers: an information theoretic approach | Bioinformatics | Oxford Academic.” Accessed: July 20, 2025. [Online]. Available: https://academic.oup.com/bioinformatics/article/34/19/3365/4991984?login=false
“Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer | Modern Pathology.” Accessed: July 20, 2025. [Online]. Available: https://www.nature.com/articles/s41379-019-0270-4
E. I. Obeagu and G. U. Obeagu, “Predictive models and biomarkers for survival in stage III breast cancer: a review of clinical applications and future directions,” Ann. Med. Surg., vol. 86, no. 10, pp. 5980–5987, Aug. 2024, doi: 10.1097/MS9.0000000000002517.
Early Breast Cancer Trialists’ Collaborative group (EBCTCG), “Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials,” Lancet Oncol., vol. 22, no. 8, pp. 1139–1150, Aug. 2021, doi: 10.1016/S1470-2045(21)00288-6.
“Current and future of targeted therapies against BCR::ABL kinases | Journal of the Egyptian National Cancer Institute | Full Text.” Accessed: July 20, 2025. [Online]. Available: https://jenci.springeropen.com/articles/10.1186/s43046-025-00263-5
“Surrogate Endpoints in Drug Development: A Review of Statistical and Regulatory Perspectives and Applications - Chen - 2025 - WIREs Computational Statistics - Wiley Online Library.” Accessed: July 20, 2025. [Online]. Available: https://wires.onlinelibrary.wiley.com/doi/abs/10.1002/wics.70014?_gl=1*nwq091*_gcl_au*MTI5ODA2NDE1MC4xNzUxMTk5MzMz*_ga*MTQ0NDIyMDg2My4xNzUxMTk5MzMy*_ga_9C4T5P6PP6*czE3NTI1MjY4MjAkbzUkZzEkdDE3NTI1MjY5NDAkajE2JGwwJGgyMDEwMzM4MDA4
“The_Evolution_of_Biomarker_Use_in_Clinical_Trials_for_Cancer_Treatments.pdf.” Accessed: July 20, 2025. [Online]. Available: https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/The_Evolution_of_Biomarker_Use_in_Clinical_Trials_for_Cancer_Treatments.pdf
“The perils of surrogate endpoints - PMC.” Accessed: July 20, 2025. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC4554958/
“Surrogate endpoints in pulmonary arterial hypertension trials - The Lancet Respiratory Medicine.” Accessed: July 20, 2025. [Online]. Available: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00190-X/abstract
O. of the Commissioner, “FDA Facts: Biomarkers and Surrogate Endpoints,” FDA, Feb. 2019, Accessed: July 20, 2025. [Online]. Available: https://www.fda.gov/about-fda/innovation-fda/fda-facts-biomarkers-and-surrogate-endpoints
“Chromatography and Separation | Biocompare.” Accessed: July 20, 2025. [Online]. Available: https://www.biocompare.com/11251-Chromatography-Separation/
A. Martinelli, “Biomarker Identification: Characteristics, Methods and Tools,” BigOmics Analytics. Accessed: July 20, 2025. [Online]. Available: https://bigomics.ch/blog/how-to-find-biomarkers-biomarker-analysis-methods-and-practical-examples/
“Troponin - StatPearls - NCBI Bookshelf.” Accessed: July 20, 2025. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK507805/
A. Bodaghi, N. Fattahi, and A. Ramazani, “Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases,” Heliyon, vol. 9, no. 2, p. e13323, Feb. 2023, doi: 10.1016/j.heliyon.2023.e13323.
“ELISA: What It Is, Purpose, Procedure & Results.” Accessed: July 20, 2025. [Online]. Available: https://my.clevelandclinic.org/health/articles/24990-elisa
“Simoa-Technologyl.pdf.” Accessed: July 20, 2025. [Online]. Available: https://humanimmunology.sites.uiowa.edu/sites/humanimmunology.sites.uiowa.edu/files/2021-09/Simoa-Technologyl.pdf
“Utilizing Digital ELISA for Precise Measurement of Brain Biomarkers in Blood | Quanterix.” Accessed: July 20, 2025. [Online]. Available: https://www.quanterix.com/utilizing-digital-elisa-for-precise-measurement-of-brain-biomarkers-in-blood/
“Single Molecule Enzyme-Linked Immunosorbent Assays: Theoretical Considerations - PMC.” Accessed: July 20, 2025. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC3327511/
S. D. Gan and K. R. Patel, “Enzyme Immunoassay and Enzyme-Linked Immunosorbent Assay,” J. Invest. Dermatol., vol. 133, no. 9, pp. 1–3, Sept. 2013, doi: 10.1038/jid.2013.287.
“Overview of ELISA | Thermo Fisher Scientific - US.” Accessed: July 20, 2025. [Online]. Available: https://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/overview-elisa.html
S. Hosseini, P. Vázquez-Villegas, M. Rito-Palomares, and S. O. Martinez-Chapa, “Advantages, Disadvantages and Modifications of Conventional ELISA,” in Enzyme-linked Immunosorbent Assay (ELISA): From A to Z, S. Hosseini, P. Vázquez-Villegas, M. Rito-Palomares, and S. O. Martinez-Chapa, Eds., Singapore: Springer, 2018, pp. 67–115. doi: 10.1007/978-981-10-6766-2_5.
“Revolutionising Biomarker Discovery: The Role of High-Performance Liquid Chromatography.” Accessed: July 21, 2025. [Online]. Available: https://www.azolifesciences.com/article/Revolutionising-Biomarker-Discovery-The-Role-of-High-Performance-Liquid-Chromatography.aspx
“Utilizing High-Performance Liquid Chromatography (HPLC) in Clinical Diagnostics | IntechOpen.” Accessed: July 21, 2025. [Online]. Available: https://www.intechopen.com/chapters/1192055
“Biomarker Discovery using Mass Spectrometry,” Danaher Life Sciences. Accessed: July 21, 2025. [Online]. Available: https://lifesciences.danaher.com/us/en/products/mass-spectrometers/topics/biomarker-discovery-using-mass-spectrometry.html
A. Habbab, N. Belboukhari, and K. Sekkoum, “Chapter 7 - Mass spectrometry,” in Analytical Techniques in Biosciences, C. Egbuna, K. C. Patrick-Iwuanyanwu, M. A. Shah, J. C. Ifemeje, and A. Rasul, Eds., Academic Press, 2022, pp. 115–124. doi: 10.1016/B978-0-12-822654-4.00016-6.
C. E. Parker and C. H. Borchers, “Mass spectrometry based biomarker discovery, verification, and validation – Quality assurance and control of protein biomarker assays,” Mol. Oncol., vol. 8, no. 4, pp. 840–858, June 2014, doi: 10.1016/j.molonc.2014.03.006.
“Mass Spectrometry Advancements and Applications for Biomarker Discovery, Diagnostic Innovations, and Personalized Medicine.” Accessed: July 21, 2025. [Online]. Available: https://www.mdpi.com/1422-0067/25/18/9880#B4-ijms-25-09880
“The_Evolution_of_Biomarker_Use_in_Clinical_Trials_for_Cancer_Treatments.pdf.” Accessed: July 20, 2025. [Online]. Available: https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/The_Evolution_of_Biomarker_Use_in_Clinical_Trials_for_Cancer_Treatments.pdf
“Liquid Chromatography-Mass Spectrometry (LC-MS) for Biomarker Discovery.” Accessed: July 21, 2025. [Online]. Available: https://www.news-medical.net/life-sciences/LC-MS-for-Biomarker-Discovery.aspx
L. Barberini, “Disease Biomarkers: A Revolutionary Approach in Modern Medicine”.
“Liquid Biopsy: What It Is & Procedure Details.” Accessed: July 21, 2025. [Online]. Available: https://my.clevelandclinic.org/health/diagnostics/23992-liquid-biopsy
R. Mayeux, “Biomarkers: Potential Uses and Limitations,” NeuroRx, vol. 1, no. 2, pp. 182–188, Apr. 2004, doi: 10.1602/neurorx.1.2.182.
K. Sechidis, K. Papangelou, P. D. Metcalfe, D. Svensson, J. Weatherall, and G. Brown, “Distinguishing prognostic and predictive biomarkers: an information theoretic approach,” Bioinformatics, vol. 34, no. 19, pp. 3365–3376, Oct. 2018, doi: 10.1093/bioinformatics/bty357.
“Challenges and Future Trends in Biomarker Analysis for Clinical Research: What’s Ahead in 2025.” Accessed: July 21, 2025. [Online]. Available: https://blog.crownbio.com/challenges-and-future-trends-in-biomarker-analysis-for-clinical-research-whats-ahead-in-2025
Downloads
Posted
Categories
License
Copyright (c) 2025 Aamna Ali
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.